Saihari Sadanandan, MD
Interventional Cardiology · Tampa, FLNPI 1457315293
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (31.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Philips North America LLC at 32.5% of the total. Reporting peaked in 2022 at $11,864 and has fallen 89.0% since, to $1,302 in 2025.
Across 237 payments — averaging $99.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$8K
- Medicure Pharma Inc.$6K
- Janssen Research & Development, LLC$2K
- Cordis US CORP.$750
- W. L. Gore & Associates, Inc.$610
- Amgen$583
- plus $5K from 41 others
Across 73 payments — averaging $7873.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$205K
- Cordis US CORP.$121K
- Philips North America LLC$73K
- Cleerly, Inc.$66K
- Amgen$54K
- Novartis$34K
- plus $22K from 2 others
What the payments were for
- Consulting fees$7,20031%
- Speaking & faculty fees$4,60020%
- Travel & lodging$4,39119%
- Food & beverage$7,34731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Aggrastat (tirofiban HCl)$6,250
- US Und$3,781
- US Enabling function$2,200
- MYNX CONTROL$750
- CARDIOFORM Septal Occluder$493
- (5027) Intact Vascular Und$446
- LIMFLOW SYSTEM$407
- PARADISE RENAL DENERVATION SYSTEM$331
- Acute cardiovascular care$200
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$171
- MitraClip$161
- Paradise Ultrasound Renal Denervation System$146
- Orsiro$145
- Pulsar$145
- PRO-Kinetic Energy$145
- PK Papyrus$145
- Astron; Pulsar; AstronPulsar$145
- IGT Devices Und$139
- (6366) Sync$122
- Indigo System$118
How this compares
$23,538 in reported general payments places this provider in the 75th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $171,537 |
| Repatha SureclickEvolocumab | 89 | $70,293 |
| EntrestoSacubitril/Valsartan | 41 | $59,107 |
| XareltoRivaroxaban | 38 | $52,784 |
| FarxigaDapagliflozin Propanediol | 24 | $18,263 |
| BrilintaTicagrelor | 16 | $13,258 |
| Praluent PenAlirocumab | 11 | $7,451 |
| ClopidogrelClopidogrel Bisulfate | 364 | $4,486 |
| Metoprolol Succinate | 262 | $2,940 |
| Atorvastatin Calcium | 255 | $2,451 |
| Midodrine Hcl | 12 | $2,071 |
| Losartan Potassium | 184 | $1,577 |
| Rosuvastatin Calcium | 105 | $1,171 |
| Lisinopril | 144 | $1,080 |
| Carvedilol | 123 | $944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $149 | $171,537132 claims |
| NovartisEntresto | $297 | $59,10741 claims |
| Johnson & JohnsonXarelto | $144 | $52,78438 claims |
| AstraZenecaFarxiga, Brilinta | $320 | $31,52140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Tampa
- Jesal PopatTampa$206K
- Bibhu MohantyTampa$171K
- Saleem SaiyadTampa$107K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.